medigraphic.com

2017, Número S2

<< Anterior Siguiente >>

Rev Mex Anest 2017; 40 (S2)


Reversión de la anticoagulación en cirugía de urgencia

Gutiérrez-Sougarret B

Idioma: Español
Referencias bibliográficas: 29
Paginas: 411-415
Archivo PDF: 195.89 Kb.


FRAGMENTO

Cada vez un mayor número de pacientes está siendo tratado con fármacos anticoagulantes y/o antiagregantes plaquetarios para la prevención de eventos tromboembólicos venosos y arteriales incluyendo el accidente vascular cerebral (AVC), la trombosis venosa profunda, la tromboembolia pulmonar y el infarto agudo del miocardio. Estos eventos son más prevalentes a medida que la población envejece. Así, en Estados Unidos en 2014, aproximadamente 15% de la población tenía 65 o más años, sin embargo, el 40% de las cirugías de ese mismo año fueron realizadas en este grupo etario(1). Debido a estos hechos, es cada vez más probable que el anestesiólogo se enfrente al problema de un paciente que se presenta para ser sometido a un procedimiento quirúrgico de urgencia y que ha estado siendo medicado con anticoagulantes y/o antiagregantes plaquetarios.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Dossett LA, Riesel JN, Griffin MR, Cotton BA. Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch Surg. 2011;146(:565-570.

  2. Harder S, Klinkhardt U, Alvarez JM. Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet. 2004;43:963-981.

  3. Adams CB, Vollman KE, Leventhal EL, Acquisto NM. Emergent pediatric anticoagulation reversal using a 4-factor prothrombin complex concentrate. Am J Emerg Med. 2016;34:1182.e1-2.

  4. Ansell JE. Reversing the effect of oral anticoagulant drugs: established and newer options. Am J Cardiovasc Drugs. 2016;16:163-170.

  5. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol. 1997;42:857-865.

  6. Stanworth SJ, Grant-Casey J, Lowe D, Laffan M, New H, Murphy MF, et al. Transfusion. The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. 2011;51:62-70.

  7. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234-1243.

  8. Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomized trial. Lancet. 2015;385:2077-2087.

  9. Voils SA, Holder MC, Premraj S, Catlin JR, Allen BR. Comparative effectiveness of 3- versus 4-factor prothrombin complex concentrate for emergent warfarin reversal. Thromb Res. 2015;136:595-598.

  10. Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325-2332.

  11. Brunton LL, Parker KL. Blood coagulation and anticoagulant, thrombolytic, and antiplatelet drugs. In: Brunton LL, Parker KL (Eds). Goodman & Gilmans manual of pharmacology and therapeutics. New York: Ed. McGraw Hill Medical; 2008. pp. 949-966.

  12. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.

  13. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131-1141.

  14. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.

  15. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511-520.

  16. Hidalgo F, Gómez-Luque A, Ferrandis R, Llau JV, de Andrés J, Gomar C, et al. Manejo perioperatorio de los anticoagulantes orales directos en cirugía urgente y sangrado. Monitorización y tratamiento hemostático. Rev Esp Anestesiol Reanim. 2015;62:450-460.

  17. Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013. Arch Cardiovasc Dis. 2013;106:382-393.

  18. Boeringer Ingelheim, Inc. Praxbind prescribing information. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf. Consultado el 22 de mayo del 2017.

  19. Boehringer Ingelheim Internaional GmbH. Praxbind summary of product characteristics. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003986/WC500197462.pdf. Consultado el 22 de mayo del 2017.

  20. Reilly PA, van Ryn J, Grottke O, Glund S, Stangier J. Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects. Am J Med. 2016;129:S64-S72.

  21. Ho PM, Peterson ED, Wang L, Magid DJ, Fihn SD, Larsen GC, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299:532-539.

  22. Yeung LYY, Babak S, Weinberg JA, et al. Surgeon’s guide to anticoagulant and antiplatelet medications part two: antipaltelet agents and perioperative management of long-term anticoagulation. Trauma Surg Acute Care Open. 2016;1:1-7.

  23. James RF, Palys V, Lomboy JR, Lamm JR Jr, Simon SD. The role of anticoagulants, antiplatelet agents, and their reversal strategies in the management of intracerebral hemorrhage. Neurosurg Focus. 2013;34:E6.

  24. Yorkgitis BK, Ruggia-Check C, Dujon JE. Antiplatelet and anticoagulation medications and the surgical patient. Am J Surg. 2014;207:95-101.

  25. Grzegorski T, Andrzejewska N, Kaźmierski R. Reversal of antithrombotic treatment in intracranial hemorrhage--A review of current strategies and guidelines. Neurol Neurochir Pol. 2015;49:278-289.

  26. Flordal PA, Sahlin S. Use of desmopressin to prevent bleeding complications in patients treated with aspirin. Br J Surg. 1993;80:723-724.

  27. Campbell PG, Sen A, Yadla S, Jabbour P, Jallo J. Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: a clinical review. World Neurosurg. 2010;74:279-285.

  28. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, et al. Normalization of platelet reactivity in clopidogrel-treated subjects. J Thromb Haemost. 2007;5:82-90.

  29. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomized, open-label, phase 3 trial. Lancet. 2016;387:2605-2613.




2020     |     www.medigraphic.com